Zobrazeno 1 - 3
of 3
pro vyhledávání: ''
Publikováno v:
Pathology and Oncology Research
Background: PD-L1 expression differs from 19 to 92% in various cancer subtypes. Its expression carries a worse prognostic value in various malignancies and could also be used as a predictive marker for immune checkpoint inhibitor response. This study
Autor:
Roberto Sánchez-Reyes, Luis Cabrera-Miranda, Héctor Aquiles Maldonado-Martínez, Suraj Samtani-Bassarmal, Oscar Arrieta, Graciela Cruz-Rico, Luis Lara-Mejía, Xitlally Popa-Navarro, Rodrigo Catalán, Dennis López-Sánchez, Alejandro Avilés-Salas
Publikováno v:
Pathology and Oncology Research
Background: Programmed cell death-ligand 1 (PD-L1) protein expression is one of the most extensively studied biomarkers in patients with non-small cell lung cancer (NSCLC). However, there is scarce information regarding its association with distinct
Autor:
Xuan Zeng, Xiaohua Shi, Yuanyuan Liu, Shafei Wu, Feng Mao, Yufeng Luo, Xuefei Wang, Jing Wang
Publikováno v:
Frontiers in Immunology
Frontiers in Immunology, Vol 12 (2021)
Frontiers in Immunology, Vol 12 (2021)
Background and AimPoor response to immune checkpoint inhibitors (ICIs) has been observed in most triple-negative breast cancer (TNBC) cases (around 80%). Our aim was to investigate the status of mismatch repair (MMR), microsatellite instability (MSI)